Explorations into the structural and molecular cerebral differences between tremor dominant and non-tremor Parkinson*s Disease

Explorations into the structural and molecular cerebral differences between tremor dominant and non-tremor Parkinson*s Disease - Tremor and non-tremor Parkinson's Disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON42970

Enrollment

Registered

2016-09-27

Start date

2016-12-12

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease tremor

Interventions

The intervention includes two fMRI sessions per subject. The patients are measured both OFF their own dopaminergic drugs, and ON 250 mg Levodopa-Benserazide + 10 mg Domperidone. During the OFF condi

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Idiopathic Parkinson*s disease according to UK brain bank criteria. - Absence of a clear resting tremor of at least one arm (UPDRS tremor-score

Exclusion criteria

Exclusion criteria: - Neurological or psychiatric co-morbidity (e.g. stroke, depression). - Severe head tremor or dyskinesias. - Cognitive impairment (MMSE

Design outcomes

Primary

Measure	Time frame
(1) Structural integrity of brain stem nuclei (substantia nigra pars compacta, retrorubral area, locus coeruleus and raphe nuclei) using DTI and SWI; (2) GABA concentrations in the thalamus both OFF and ON dopaminergic therapy; (3) Cognitive performance on dopamine-dependent (go/nogo) and dopamine-independent (paired associative learning) behavioural task. (4) functional connectivity at rest, both OFF and ON dopaminergic therapy;	—

Measure

Time frame

(1) Structural integrity of brain stem nuclei (substantia nigra pars compacta, retrorubral area, locus coeruleus and raphe nuclei) using DTI and SWI; (2) GABA concentrations in the thalamus both OFF and ON dopaminergic therapy; (3) Cognitive performance on dopamine-dependent (go/nogo) and dopamine-independent (paired associative learning) behavioural task. (4) functional connectivity at rest, both OFF and ON dopaminergic therapy;

—

Secondary

Measure	Time frame
- Result of clinical assessment of cognitive function (MMSE, FAB). - Result of clinical assessment of parkinsonian symptom severity (TRS, UPDRS) before and after medication.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)